Estimation of Metabolic Rate Constants in PBPK‐Models from Liver Slice Experiments: What Are the Experimental Needs?

A mechanistic model is presented describing the clearance of a compound in a precision-cut liver slice that is incubated in a culture medium. The problem of estimating metabolic rate constants in PBPK models from liver slice experiments is discussed using identifiability analysis. From the identifiability problem analysis, it appears that in addition to the clearance, the compound's free fraction in the slice and the diffusion rate of the exchange of the compound between culture medium and liver slice should be identified. In addition, knowledge of the culture medium volume, the slice volume, the compound's free fraction, and octanol-water-based partition between medium and slice is presupposed. The formal solution for identification is discussed from the perspective of experimental practice. A formally necessary condition for identification is the sampling of parent compound in liver slice or culture medium. However, due to experimental limitations and errors, sampling the parent compound in the slice together with additional sampling of metabolite pooled from the medium and the slice is required for identification in practice. Moreover, it appears that identification results are unreliable when the value of the intrinsic clearance exceeds the value of the diffusion coefficient, a condition to be verified a posteriori.     

Benchmark Analysis: Shopping with Proper Confidence

We discuss the issue of using benchmark doses for quantifying (excess) risk associated with exposure to environmental hazards. The paradigm of low-dose risk estimation in dose-response modeling is used as the primary application scenario. Emphasis is placed on making simultaneous inferences on benchmark doses when data are in the form of proportions, although the concepts translate easily to other forms of outcome data.     

Physiologically Based Liver Modeling and Risk Assessment

Because of the inherent complexity of biological systems, there is often a choice between a number of apparently equally applicable physiologically based models to describe uptake and metabolism processes in toxicology or risk assessment. These models may fit the particular data sets of interest equally well, but may give quite different parameter estimates or predictions under different (extrapolated) conditions. Such competing models can be discriminated by a number of methods, including potential refutation by means of strategic experiments, and their ability to suitably incorporate all relevant physiological processes. For illustration, three currently used models for steady-state hepatic elimination--the venous equilibration model, the parallel tube model, and the distributed sinusoidal perfusion model--are reviewed and compared with particular reference to their application in the area of risk assessment. The ability of each of the models to describe and incorporate such physiological processes as protein binding, precursor-metabolite relations and hepatic zones of elimination, capillary recruitment, capillary heterogeneity, and intrahepatic shunting is discussed. Differences between the models in hepatic parameter estimation, extrapolation to different conditions, and interspecies scaling are discussed, and criteria for choosing one model over the others are presented. In this case, the distributed model provides the most general framework for describing physiological processes taking place in the liver, and has so far not been experimentally refuted, as have the other two models. These simpler models may, however, provide useful bounds on parameter estimates and on extrapolations and risk assessments.     

Bias correction for parameter estimates of spatial point process models

When a spatial point process model is fitted to spatial point pattern data using standard software, the parameter estimates are typically biased. Contrary to folklore, the bias does not reflect weaknesses of the underlying mathematical methods, but is mainly due to the effects of discretization of the spatial domain. We investigate two approaches to correcting the bias: a Newton–Raphson-type correction and Richardson extrapolation. In simulation experiments, Richardson extrapolation performs best.     

Subsampling-extrapolation bandwidth selection in bivariate kernel density estimation

This paper focuses on bivariate kernel density estimation that bridges the gap between univariate and multivariate applications. We propose a subsampling-extrapolation bandwidth matrix selector that improves the reliability of the conventional cross-validation method. The proposed procedure combines a U-statistic expression of the mean integrated squared error and asymptotic theory, and can be used in both cases of diagonal bandwidth matrix and unconstrained bandwidth matrix. In the subsampling stage, one takes advantage of the reduced variability of estimating the bandwidth matrix at a smaller subsample size m (m < n); in the extrapolation stage, a simple linear extrapolation is used to remove the incurred bias. Simulation studies reveal that the proposed method reduces the variability of the cross-validation method by about 50% and achieves an expected integrated squared error that is up to 30% smaller than that of the benchmark cross-validation. It shows comparable or improved performance compared to other competitors across six distributions in terms of the expected integrated squared error. We prove that the components of the selected bivariate bandwidth matrix have an asymptotic multivariate normal distribution, and also present the relative rate of convergence of the proposed bandwidth selector.     

Statistical modeling for Bayesian extrapolation of adult clinical trial information in pediatric drug evaluation

Children represent a large underserved population of “therapeutic orphans,” as an estimated 80% of children are treated off‐label. However, pediatric drug development often faces substantial challenges, including economic, logistical, technical, and ethical barriers, among others. Among many efforts trying to remove these barriers, increased recent attention has been paid to extrapolation; that is, the leveraging of available data from adults or older age groups to draw conclusions for the pediatric population. The Bayesian statistical paradigm is natural in this setting, as it permits the combining (or “borrowing”) of information across disparate sources, such as the adult and pediatric data. In this paper, authored by the pediatric subteam of the Drug Information Association Bayesian Scientific Working Group and Adaptive Design Working Group, we develop, illustrate, and provide suggestions on Bayesian statistical methods that could be used to design improved pediatric development programs that use all available information in the most efficient manner. A variety of relevant Bayesian approaches are described, several of which are illustrated through 2 case studies: extrapolating adult efficacy data to expand the labeling for Remicade to include pediatric ulcerative colitis and extrapolating adult exposure‐response information for antiepileptic drugs to pediatrics.     

A Semiparametric Approach for Accelerated Failure Time Models with Covariates Subject to Measurement Error

There are relatively few discussions about measurement error in the accelerated failure time (AFT) model, particularly for the semiparametric AFT model. In this article, we propose an adjusted estimation procedure for the semiparametric AFT model with covariates subject to measurement error, based on the profile likelihood approach and simulation and exploration (SIMEX) method. The simulation studies show that the proposed semiparametric SIMEX approach performs well. The proposed approach is applied to a coronary heart disease dataset from the Busselton Health study for illustration.     

Biologically Motivated Cancer Risk Models

A two-stage dose response model is proposed for use in cancer risk assessment. The model assumes that transformation probabilities and cellular dynamics are exposure- and time-dependent.     

Generic Assessment Endpoints Are Needed for Ecological Risk Assessment

This article presents arguments for the development of generic assessment endpoints for ecological risk assessment. Generic assessment endpoints would be ecological entities and attributes that are assumed to be worthy of protection in most contexts. The existence of generic assessment endpoints would neither create a requirement that they be used in every assessment nor preclude the use of other assessment endpoints. They would simply be a starting point in the process of identifying the assessment endpoints for a particular assessment. They are needed to meet legal mandates, to provide a floor for environmental degradation, to provide some consistency in environmental regulation, as exemplars for site- or project-specific assessment endpoints, to allow development of methods and models, to give risk managers the courage to act, for screening and site-independent assessments, to support environmental monitoring, to facilitate communication, and to avoid paralysis by analysis. Generic assessment endpoints should include not only a list of entities and attributes, but also explanations of each endpoint, guidance on their use and interpretation, and measures and models that could be used to estimate them.